{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:11:58Z","timestamp":1790327518615,"version":"4.1.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>\n                    Immune checkpoint inhibitors targeting the PD-1\/PD-L1 axis have substantially improved the treatment of lung cancer, yet durable responses remain limited by primary and acquired resistance. Increasing evidence identifies the PI3K\/AKT\/mTOR pathway as a central link between oncogenic signaling, metabolic adaptation, and tumor immune suppression. Genetic and molecular alterations, including PIK3CA activation, PTEN loss, and aberrant EGFR or ALK signaling, can activate this pathway and regulate PD-L1 expression at transcriptional, translational, and post-translational levels. Conversely, tumor-intrinsic PD-L1 signaling can reinforce PI3K\/AKT\/mTOR activity, promoting proliferation, survival, glycolysis, epithelial\u2013mesenchymal transition, and resistance to therapy. This reciprocal interaction establishes a feedforward circuit that supports lung cancer progression and immune escape. The pathway also reshapes the tumor microenvironment by promoting regulatory T-cell expansion, M2-like macrophage polarization, myeloid-cell recruitment, CD8\n                    <jats:sup>+<\/jats:sup>\n                    T-cell dysfunction, and resistance to immune checkpoint blockade. This review critically examines the bidirectional crosstalk between PI3K\/AKT\/mTOR and PD-1\/PD-L1 signaling in lung cancer and summarizes the molecular regulators that connect these pathways. We further discuss therapeutic strategies designed to disrupt this network, including PI3K, AKT, and mTOR inhibitors; targeted therapies; chemotherapy and radiotherapy combinations; antiangiogenic approaches; nanomedicine; extracellular-vesicle-based delivery; cell-based interventions; and natural compounds. Although preclinical evidence supports combining pathway inhibition with immune checkpoint blockade, clinical translation is challenged by pathway complexity, context-dependent regulation of PD-L1, systemic toxicity, and the absence of validated predictive biomarkers. Biomarker-guided patient selection, optimized dosing and sequencing, and selective targeting of tumor- or immune-cell-specific pathway components will therefore be essential for converting this mechanistic rationale into durable clinical benefit.\n                  <\/jats:p>","DOI":"10.3389\/fcell.2026.1952310","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:48:40Z","timestamp":1790326120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PI3K\/AKT\/mTOR signaling at the immune checkpoint interface in lung cancer: molecular mechanisms, Tumor\u2013Immune remodeling, therapeutic resistance, and emerging treatment strategies"],"prefix":"10.3389","volume":"14","author":[{"given":"Hongliang","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital (Shenyang Chest Hospital)","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital (Shenyang Chest Hospital)","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital (Shenyang Chest Hospital)","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shenyang Tenth People\u2019s Hospital (Shenyang Chest Hospital)","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.7150\/jca.14713","article-title":"AKT-STAT3 pathway as a downstream target of EGFR signaling to regulate PD-L1 expression on NSCLC cells","volume":"7","author":"Abdelhamed","year":"2016","journal-title":"J. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.ccr-22-3949","article-title":"Autocrine 17-\u03b2-Estradiol\/Estrogen Receptor-\u03b1 loop determines the response to immune checkpoint inhibitors in non\u2013small cell lung cancer","volume":"29","author":"Anobile","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca. Cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.3390\/cancers13164040","article-title":"PI3K\/Akt pathway: the indestructible role of a vintage target as a support to the Most recent immunotherapeutic approaches","volume":"13","author":"Caforio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.bioactmat.2025.07.042","article-title":"Inhibition of ARH2 by pH\/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy","volume":"53","author":"Cai","year":"2025","journal-title":"Bioact. Mat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3390\/cancers12030666","article-title":"Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by Anti-PD-L1 antibody therapy in non-small-cell lung cancer","volume":"12","author":"Cavazzoni","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","article-title":"ILT4 inhibition prevents TAM-And dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation","volume":"11","author":"Chen","year":"","journal-title":"Theranostics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"674856","DOI":"10.3389\/fgene.2021.674856","article-title":"LncRNA SOX2-OT\/miR-30d-5p\/PDK1 regulates PD-L1 checkpoint through the mTOR signaling pathway to promote non-small cell lung cancer progression and immune escape","volume":"12","author":"Chen","year":"","journal-title":"Front. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1038\/s41388-024-03194-y","article-title":"MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma","volume":"43","author":"Chen","year":"2024","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"156093","DOI":"10.1016\/j.phymed.2024.156093","article-title":"Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization","volume":"135","author":"Cheng","year":"2024","journal-title":"Phytomedicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/cancers11091318","article-title":"PTEN alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 inhibition","volume":"11","author":"Cretella","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1038\/s41388-019-0877-4","article-title":"Inhibition of mTOR complex 1\/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced \u03b2-TrCP degradation","volume":"38","author":"Deng","year":"2019","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12931-023-02656-3","article-title":"Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-Sensitive mutations","volume":"25","author":"Ding","year":"2024","journal-title":"Respir. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1158\/0008-5472.CAN-22-3023","article-title":"PTEN loss confers resistance to Anti\u2013PD-1 therapy in non\u2013small cell lung cancer by increasing tumor infiltration of regulatory T cells","volume":"83","author":"Exposito","year":"2023","journal-title":"Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"130439","DOI":"10.1016\/j.bbagen.2023.130439","article-title":"Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells","volume":"1867","author":"Fu","year":"2023","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1007\/s12094-024-03444-1","article-title":"Potential of Semen coicis in enhancing the anti-tumor effects of PD-1 inhibitor on A549 cell lines by blocking the PI3K-AKT-mTOR pathway","volume":"26","author":"Fu","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ijc.31357","article-title":"IFN-\u03b3-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling","volume":"143","author":"Gao","year":"2018","journal-title":"Int. J. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined radiotherapy and Anti\u2013PD-L1 antibody synergistically enhances antitumor effect in non\u2013small cell lung cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e3925","DOI":"10.1002\/cbf.3925","article-title":"Amplifying T cell-mediated antitumor immune responses in nonsmall cell lung cancer through photodynamic therapy and anti-PD1","volume":"42","author":"Gong","year":"2024","journal-title":"Cell biochem. Funct."},{"key":"B20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.4103\/jcrt.JCRT_636_18","article-title":"mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase\/AKT\/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma","volume":"15","author":"Han","year":"2019","journal-title":"J. Cancer Res. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.21037\/atm-20-5865","article-title":"Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis","volume":"8","author":"Hu","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.3390\/molecules26134100","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway in lung cancer: an update regarding potential drugs and natural products","volume":"26","author":"Iksen","year":"2021","journal-title":"Molecules"},{"key":"B23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.biopha.2017.09.129","article-title":"Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune","volume":"96","author":"Jiang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12935-019-0789-y","article-title":"Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells","volume":"19","author":"Jiang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13578-020-00499-9","article-title":"KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K\/PD-L1 axis activity","volume":"10","author":"Jiang","year":"2020","journal-title":"Cell Biosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41698-025-00949-y","article-title":"HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype","volume":"9","author":"Jiang","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12951-025-03456-1","article-title":"Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems","volume":"23","author":"Jin","year":"2025","journal-title":"J. Nanobiotechnology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e70298","DOI":"10.1111\/cbdd.70298","article-title":"Cepharanthine reverses gefitinib resistance in NSCLC by concurrently inhibiting AKT\/P70S6K survival signaling and activating STING-mediated immune response","volume":"107","author":"Kang","year":"2026","journal-title":"Chem. Biol. Drug Des."},{"key":"B29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s13046-019-1407-5","article-title":"Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer","volume":"38","author":"Kim","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non\u2013small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"B32","first-page":"5443","article-title":"Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1\/PD-1 inhibitors in lung adenocarcinoma","volume":"13","author":"Lee","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3892\/or.2018.6474","article-title":"Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process","volume":"40","author":"Li","year":"2018","journal-title":"Oncol. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"115891","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41467-024-45340-w","article-title":"UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.3390\/cells10092488","article-title":"Statins decrease programmed death-ligand 1 (PD-L1) by inhibiting AKT and \u03b2-Catenin signaling","volume":"10","author":"Lim","year":"2021","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e23401","DOI":"10.1002\/jbt.23401","article-title":"Bakuchiol inhibits lung cancer by modulating tumor microenvironment and the expression of PD-L1","volume":"37","author":"Lin","year":"2023","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1016\/j.apsb.2021.03.039","article-title":"Tubeimoside-1 induces TFEB-Dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR","volume":"11","author":"Liu","year":"","journal-title":"Acta Pharm. Sin. B"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10955","DOI":"10.3390\/ijms222010955","article-title":"L-Type amino acid transporter 1 regulates cancer stemness and the expression of programmed cell death 1 ligand 1 in lung cancer cells","volume":"22","author":"Liu","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"105302","DOI":"10.1016\/j.jbc.2023.105302","article-title":"BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non\u2013small cell lung cancer","volume":"299","author":"Liu","year":"2023","journal-title":"J. Biol. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"167262","DOI":"10.1016\/j.bbadis.2024.167262","article-title":"Combined cryoablation and PD-1 inhibitor synergistically enhance antitumor immune responses in lewis lung adenocarcinoma mice via the PI3K\/AKT\/mTOR pathway","volume":"1870","author":"Liu","year":"2024","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41419-025-07685-y","article-title":"Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC","volume":"16","author":"Liu","year":"2025","journal-title":"Cell Death Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e23195","DOI":"10.1096\/fj.202300687rr","article-title":"RUNX1 promotes proliferation and migration in non\u2010small cell lung cancer cell lines via the mTOR pathway","volume":"37","author":"Ma","year":"2023","journal-title":"FASEB J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1111\/cas.14529","article-title":"Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells","volume":"111","author":"Mao","year":"2020","journal-title":"Cancer Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"RP98258","DOI":"10.7554\/eLife.98258","article-title":"NPRL2 gene therapy induces effective antitumor immunity in KRAS\/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model","volume":"13","author":"Meraz","year":"2025","journal-title":"Elife"},{"key":"B48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/diseases12050093","article-title":"Unravelling the triad of lung cancer, drug resistance, and metabolic pathways","volume":"12","author":"Mohanty","year":"2024","journal-title":"Diseases"},{"key":"B49","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbrc.2018.11.035","article-title":"Interferon-\u03b2 signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells","volume":"507","author":"Morimoto","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3390\/ijms18112473","article-title":"Akt1 stimulates homologous recombination repair of DNA double-strand breaks in a Rad51-Dependent manner","volume":"18","author":"Mueck","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-017-1986-y","article-title":"PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer","volume":"66","author":"Okita","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4\u2013ALK oncoprotein and downstream signaling pathways in non\u2013small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e31825493eb","article-title":"Development of PI3K\/AKT\/mTOR pathway inhibitors and their application in personalized therapy for Non\u2013small-cell lung cancer","volume":"7","author":"Papadimitrakopoulou","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-Cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1516583","DOI":"10.3389\/fphar.2025.1516583","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in lung cancer: mechanisms and therapeutic targeting","volume":"16","author":"Qiang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1758835921992968","DOI":"10.1177\/1758835921992968","article-title":"The progress and challenge of anti-PD-1\/PD-L1 immunotherapy in treating non-small cell lung cancer","volume":"13","author":"Qu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J. Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/cancers13163949","article-title":"The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review","volume":"13","author":"Rascio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/molecules23082071","article-title":"Green tea catechin is an alternative immune checkpoint inhibitor that inhibits PD-L1 expression and lung tumor growth","volume":"23","author":"Rawangkan","year":"2018","journal-title":"Molecules"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in Non\u2013small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/cells10071632","article-title":"Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells","volume":"10","author":"Rugamba","year":"2021","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","first-page":"eadi2046","DOI":"10.1126\/sciadv.adi2046","article-title":"Antibody nanoparticle conjugate\u2013based targeted immunotherapy for non\u2013small cell lung cancer","volume":"10","author":"Saha","year":"2024","journal-title":"Sci. Adv."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101364","DOI":"10.1016\/j.tranon.2022.101364","article-title":"The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles","volume":"18","author":"Sanaei","year":"2022","journal-title":"Transl. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.celrep.2015.09.007","article-title":"Akt kinase-mediated checkpoint of cGAS DNA sensing pathway","volume":"13","author":"Seo","year":"2015","journal-title":"Cell Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13046-024-03122-8","article-title":"CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN\/AKT signaling phosphorylation and neutrophil chemotaxis","volume":"43","author":"Sun","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e202451118","DOI":"10.1002\/eji.202451118","article-title":"Ubiquitin\u2010conjugating enzyme Ubc13 in macrophages suppresses lung tumor progression through inhibiting PD\u2010L1 expression","volume":"55","author":"Sun","year":"2025","journal-title":"Eur. J. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.32604\/or.2026.071536","article-title":"Lactic acid drives ESM1 to attenuate DNA damage and CD8+ T cell infiltration in cancer","volume":"34","author":"Tan","year":"2026","journal-title":"Oncol. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"105086","DOI":"10.1016\/j.phrs.2020.105086","article-title":"HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila","volume":"160","author":"Teng","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"107395","DOI":"10.1016\/j.intimp.2021.107395","article-title":"Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1\/2 signaling pathways in non-small cell lung cancer","volume":"93","author":"Tian","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e10225","DOI":"10.7717\/peerj.10225","article-title":"ZFPM2-AS1 promotes the proliferation, migration, and invasion of human non-small cell lung cancer cells involving the JAK-STAT and AKT pathways","volume":"8","author":"Wang","year":"","journal-title":"PeerJ"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","article-title":"Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy","volume":"117","author":"Wang","year":"","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1227797","DOI":"10.3389\/fimmu.2023.1227797","article-title":"Research progress of biomarkers in the prediction of anti-PD-1\/PD-L1 immunotherapeutic efficiency in lung cancer","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1002\/ctm2.1786","article-title":"Single-cell transcriptome analysis deciphers the CD74-mediated immune evasion and tumour growth in lung squamous cell carcinoma with chronic obstructive pulmonary disease","volume":"14","author":"Wang","year":"","journal-title":"Clin. Transl. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3892\/ol.2024.14700","article-title":"PI3K\/AKT\/mTOR and PD-1\/CTLA-4\/CD28 pathways as key targets of cancer immunotherapy","volume":"28","author":"Wang","year":"","journal-title":"Oncol. Lett."},{"key":"B75","doi-asserted-by":"publisher","first-page":"109746","DOI":"10.1016\/j.biopha.2019.109746","article-title":"Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in lewis lung carcinoma mouse model","volume":"125","author":"Wu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.4081\/ejh.2024.4098","article-title":"Astragaloside IV augments anti-PD-1 therapy to suppress tumor growth in lung cancer by remodeling the tumor microenvironment","volume":"68","author":"Wu","year":"2024","journal-title":"Eur. J. Histochem. EJH"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/1759-7714.13533","article-title":"Tobacco extracts promote PD\u2010L1 expression and enhance malignant biological differences via mTOR in gefitinib\u2010resistant cell lines","volume":"11","author":"Xiao","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1554467","DOI":"10.3389\/fimmu.2025.1554467","article-title":"Study on the efficacy of IFN-\u03b3- and sPD-1-overexpressing BMSCs in enhancing immune effects for the treatment of lung adenocarcinoma","volume":"16","author":"Xie","year":"2025","journal-title":"Front. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"123599","DOI":"10.1016\/j.lfs.2025.123599","article-title":"The crosstalk between lung adenocarcinoma cells and M2 macrophages promotes cancer cell development via the SFRS1\/miR-708-5p\/PD-L1 axis","volume":"371","author":"Xu","year":"2025","journal-title":"Life Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5483\/BMBRep.2021.54.1.241","article-title":"Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity","volume":"54","author":"Yadollahi","year":"2021","journal-title":"BMB Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1038\/s41467-021-25032-5","article-title":"USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/0008-5472.CAN-22-3009","article-title":"TGF\u03b2 antagonizes IFN\u03b3-Mediated adaptive immune evasion via activation of the AKT\u2013Smad3\u2013SHP1 axis in lung adenocarcinoma","volume":"83","author":"Ye","year":"2023","journal-title":"Cancer Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.7150\/thno.42234","article-title":"BBB-Penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation","volume":"10","author":"Yin","year":"2020","journal-title":"Theranostics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s43556-024-00225-8","article-title":"Unveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer","volume":"5","author":"Yin","year":"2024","journal-title":"Mol. Biomed."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mc.23005","article-title":"Epimagnolin targeting on an active pocket of Mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells","volume":"58","author":"Yoo","year":"2019","journal-title":"Mol. Carcinog."},{"key":"B86","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41419-020-2701-z","article-title":"PD-L1 promotes tumor growth and progression by activating WIP and \u03b2-catenin signaling pathways and predicts poor prognosis in lung cancer","volume":"11","author":"Yu","year":"2020","journal-title":"Cell Death Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/cas.13072","article-title":"Upregulation of programmed cell death ligand 1 promotes resistance response in non\u2010small\u2010cell lung cancer patients treated with neo\u2010adjuvant chemotherapy","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-18-2548","article-title":"A novel mTORC1\/2 inhibitor (MTI-31) inhibits tumor growth, epithelial\u2013mesenchymal transition, metastases, and improves antitumor immunity in preclinical models of lung cancer","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"595466","DOI":"10.3389\/fonc.2020.595466","article-title":"Eliminating radiation resistance of non-small cell lung cancer by dihydroartemisinin through abrogating immunity escaping and promoting radiation sensitivity by inhibiting PD-L1 expression","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1952310\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:48:42Z","timestamp":1790326122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1952310\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":90,"alternative-id":["10.3389\/fcell.2026.1952310"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1952310","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1952310"}}